Welcome!

News Feed Item

MYOS Corporation Reports 2014 First Quarter Results

CEDAR KNOLLS, NJ -- (Marketwired) -- 05/16/14 -- MYOS Corporation (OTCBB: MYOS)

  • Company Well Positioned to Achieve Significant Near-Term Milestones by Year End
  • Research and Development Programs Exploring Fortetropin™ as Potential Treatment Option in Muscle Health and Sarcopenia Progressing in Multiple Clinical Studies

MYOS Corporation (OTCBB: MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance ("MYOS" or the "Company"), announced today its financial results for the first quarter ended March 31, 2014 and provided highlights of the Company's recent progress and anticipated near-term research and development milestones for Fortetropin™ (also known as MYO-T12®), the first clinically proven natural myostatin inhibitor.

"Since the commercial launch of our first Fortetropin-powered bionutrition product, MYO-X™, the Company has successfully created a solid growth and revenue engine, with total net revenues since inception approaching $6 million. We see our growing bionutrition revenues as an important means of accelerating investment in research and development. The Company is leveraging the expertise developed in advancing its bionutrition business to build a biotherapeutics portfolio of small molecules and other compounds which can be applied to the increasingly important clinical conditions in muscle health," said Robert J. Hariri, M.D., Ph.D., Chairman of the Board of MYOS. "During the first quarter we enhanced our commitment to our clinical research by strengthening our management team with a highly experienced Chief Medical Officer. We also initiated two additional clinical studies to further evaluate the effects of Fortetropin on myostatin inhibition in an effort to explore potential opportunities for expansion of our age-management pipeline. We believe that our team's continued dedication to our emerging muscle health therapeutic development program will enable MYOS to provide innovative solutions for multiple potential indications including sarcopenia, cachexia and age-associated muscle loss treatments in age-management."

FIRST QUARTER AND RECENT HIGHLIGHTS

  • Reported first quarter 2014 net revenues of $1.55 million, an increase of 457% compared to the first quarter of 2013;
  • Initiated a clinical study on Fortetropin's effect on skeletal muscle mass and strength in resistance-trained male subjects;
  • Sponsored the upcoming Cancer Cachexia 2014 conference highlighting evolving mechanisms and therapies for treating debilitating muscle wasting syndrome related to cancer;
  • Partnered with the Muscular Dystrophy Association (MDA) to raise funds and awareness for MDA's fight against degenerative muscle disease;
  • Launched an educational portal on sarcopenia (www.sarcopeniacure.com) in conjunction with the Aging in Motion awareness campaign working to develop measures of clinical benefit for therapeutic products to treat sarcopenia;
  • Presented lipidomic and proteomic characterization data on Fortetropin at the 2014 International Conference on Frailty and Sarcopenia Research and published an abstract in Journal of Frailty and Aging providing new insights into mechanisms by which Fortetropin may exert its beneficial effects on muscle;
  • Initiated a clinical study on the effects of Fortetropin on blood chemistry, body mass index, waist circumference and other indices of muscle health in adult women;
  • Appointed Wall Street investment veteran, Christopher Pechock, to the Board of Directors;
  • Appointed experienced healthcare industry leader and clinician, Robert C. Ashton, Jr., M.D., as Chief Medical Officer; and
  • Closed $4.735 million in private equity financing followed by a 1-for-50 reverse stock split.

NEAR-TERM MILESTONES

  • Clinical study data on Fortetropin in muscle and strength building activity in resistance-trained men expected by the end of the second quarter of 2014;
  • Results of Fortetropin study in adult women expected early in the fourth quarter of 2014;
  • Anticipate strategic collaboration for Fortetropin in age management market;
  • Pre-clinical data on synergistic effects of myostatin inhibition on testosterone-mediated muscle growth expected in the second half of 2014;
  • Formulation of liquid bionutrition Fortetropin product targeted for year-end; and
  • Expansion of Board of Directors and Scientific Advisory Board anticipated to begin this year.

Peter Levy, MYOS' President and Chief Operating Officer added, "For the remainder of 2014 the MYOS team will be laser-focused on advancing our clinical pipeline and expanding Fortetropin in the age-management market and for additional therapeutic opportunities. The Company's patent strategy is sound and we will continue to rigorously pursue additional enhancements to our IP portfolio. By the end of the year we expect to have data from three studies, which we believe will be key to transforming the Company into its next phase of growth as a biotherapeutic leader in age-management and muscle health. We believe MYOS is well-positioned to capitalize on the strategic and commercial prospects for Foretropin and represents an opportunity for a broad group of investors attracted to small-to-mid cap companies interested in maximizing shareholder return."

FIRST QUARTER 2014 FINANCIAL SUMMARY

For the first quarter of 2014, the Company's net revenues were approximately $1,546,000 compared to net revenues of approximately $277,000 for the first quarter of 2013 and approximately $1,408,000 for the fourth quarter of 2013. Net revenues for the trailing twelve months was approximately $4,587,000.

Loss from operations was approximately $423,000 for the first quarter of 2014 compared to approximately $1,092,000 for the first quarter of 2013 and approximately $1,409,000 for the fourth quarter of 2013. Operating losses include the Company's investment in research and development activities in the first quarter of 2014 of approximately $434,000 compared to approximately $178,000 in the first quarter of 2013 and approximately $356,000 in the fourth quarter of 2013.

Net loss for the first quarter of 2014 was approximately $422,000 compared to approximately $1,090,000 for the first quarter of 2013 and approximately $1,408,000 for the fourth quarter of 2013. Basic and diluted net loss per share was $(0.16) for the first quarter of 2014 compared to $(0.47) for the first quarter of 2013 and $(0.64) for the fourth quarter of 2013. Per share results are based on weighted average shares outstanding of 2.703 million for the first quarter of 2014 compared to 2.295 million for the first quarter of 2013 and 2.217 million for the fourth quarter of 2013.

On a non-GAAP basis, net loss for the first quarter of 2014 was approximately $119,000 compared to approximately $736,000 for the first quarter of 2013. Non-GAAP basic and diluted net loss per share was $(0.04) for the first quarter of 2014 compared to $(0.32) for the first quarter of 2013. Non-GAAP net loss excludes stock-based compensation of approximately $303,000 for the first quarter of 2014 compared to approximately $354,000 for the first quarter of 2013.

The Company had cash of approximately $3,914,000 and total assets of $8,964,000 as of March 31, 2014 compared to cash of approximately $451,000 and total assets of $3,836,000 as of December 31, 2013.

In addition to the GAAP financial measures set forth in this press release, the Company has included non-GAAP net loss and non-GAAP basic and diluted net loss per share measures, which present results on a basis adjusted for certain items. Non-GAAP net loss and non-GAAP basic and diluted net loss per share are supplemental measures of our performance that are not required by, or presented in accordance with, GAAP. The Company uses these non-GAAP measures as key performance measures for the purpose of evaluating performance internally. The Company also believes these non-GAAP measures provide the Company's investors with useful information regarding the Company's historical operating results. These non-GAAP measures are not intended to replace the presentation of the Company's financial results in accordance with GAAP. Use of the terms non-GAAP net loss, and non-GAAP basic and diluted net loss per share may differ from similar measures reported by other companies. We define non-GAAP net loss as net loss adjusted for stock-based compensation and certain special charges that are otherwise included in GAAP net loss, including changes in fair value of warrants, amortization of deferred financing costs and impairment charges. Non-GAAP basic and diluted net loss per share refers to non-GAAP net loss divided by the weighted average number of basic and diluted shares outstanding. All of the non-GAAP measures discussed above are reconciled from their respective GAAP measures in the attached table "Reconciliation of GAAP to non-GAAP Net Loss" table set forth below.

A summary of key financial highlights for the three months ended March 31, 2014 and 2013 is as follows:


                      MYOS CORPORATION AND SUBSIDIARY
                       (a development stage company)
                   CONSOLIDATED STATEMENTS OF OPERATIONS
                                (Unaudited)
                                                                April 11,
                                                                   2007
                                                                (Inception
                                                                  Date)
                                Three Months Ended March 31,   to March 31,
                                     2014           2013           2014
                                -------------  -------------  -------------
Net revenue                     $   1,546,334  $     277,374  $   5,875,421
Cost of sales                         404,774        126,989      2,838,896
                                -------------  -------------  -------------
  Gross profit                      1,141,560        150,385      3,036,525
Operating expenses                  1,564,638      1,242,444     15,504,721
                                -------------  -------------  -------------
  Loss from operations               (423,078)    (1,092,059)   (12,468,196)

  Other Income (Expense)
  Interest income                       1,189          1,865         14,068
  Interest expense                        (14)             -       (827,044)
  Value of warrants in excess of
   the amount of additional
   paid-in capital received in
   the related private placement
   of restricted common stock               -              -     (2,405,303)
    Change in fair value of
     warrants                               -              -      4,085,570
    Impairment charge -
     intellectual property                  -              -     (2,662,000)
    Amortization of deferred
     financing costs                        -              -        (80,000)
    Gain on forgiveness of debt             -              -         12,500
                                -------------  -------------  -------------
Total other income (expense)            1,175          1,865     (1,862,209)
                                -------------  -------------  -------------

Net loss                             (421,903)    (1,090,194)   (14,330,405)
                                =============  =============  =============

Weighted average number of
 common shares outstanding,
 basic and diluted                  2,703,341      2,295,349

Basic and diluted net loss per
 share attributable to common
 stockholders                   $       (0.16) $       (0.47)
                                =============  =============



                      MYOS CORPORATION AND SUBSIDIARY
                       (a development stage company)
                        CONSOLIDATED BALANCE SHEETS

                                                   March 31,   December 31,
                                                     2014          2013
                                                 ------------  ------------
                                                  (Unaudited)
ASSETS
Current assets
Cash                                             $  3,913,705  $    451,361
Accounts receivable                                 1,494,879       644,760
Inventories                                           860,572       142,430
Prepaid expenses and other current assets             319,580       215,128
                                                 ------------  ------------
Total current assets                                6,588,736     1,453,679
Fixed assets, net of accumulated depreciation         336,398       344,366
Intellectual property                               2,000,000     2,000,000
Intangible assets                                      38,652        38,377
                                                 ------------  ------------
Total assets                                     $  8,963,786  $  3,836,422
                                                 ============  ============

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable                                 $    710,210  $    184,685
Accrued expenses                                      369,578       311,704
                                                 ------------  ------------
Total current liabilities                           1,079,788       496,389
                                                 ------------  ------------

Total liabilities                                   1,079,788       496,389
                                                 ------------  ------------

Commitments and contingencies

Stockholders' equity
Preferred stock, $.001 par value; 500,000 shares
 authorized; no shares issued and outstanding               -             -
Common stock, $.001 par value, 6,000,000 shares
 authorized; 2,919,235 and 2,227,447 shares
 issued and outstanding at March 31, 2014 and
 December 31, 2013, respectively                        2,918         2,227
Additional paid-in capital                         22,211,485    17,246,308
Deficit accumulated during development stage      (14,330,405)  (13,908,502)
                                                 ------------  ------------
Total stockholders' equity                          7,883,998     3,340,033
                                                 ------------  ------------

Total liabilities and stockholders' equity       $  8,963,786  $  3,836,422
                                                 ============  ============



                      MYOS CORPORATION AND SUBSIDIARY
                       (a development stage company)
                Reconciliation of GAAP to Non-GAAP Net Loss
                                (Unaudited)
                                                                 April 11,
                                                                   2007
                                                                (Inception
                                                                   Date)
                                 Three Months Ended March 31,  to March 31,
                                      2014           2013          2014
                                 -------------  -------------  ------------
GAAP - net loss                       (421,903)    (1,090,194)  (14,330,405)

Stock-based compensation               302,911        354,372     4,985,132
Change in fair value of warrants             -              -    (4,085,570)
Amortization of deferred
 financing costs                             -              -        80,000
Impairment charges                           -              -     2,662,000

                                 -------------  -------------  ------------
Non-GAAP - net loss                   (118,992)      (735,822)  (10,688,843)
                                 -------------  -------------  ------------

Weighted average number of common
 shares outstanding, basic and
 diluted                             2,703,341      2,295,349

GAAP basic and diluted net loss
 per share                       $       (0.16) $       (0.47)

Non-GAAP basic and diluted net
 loss per share                  $       (0.04) $       (0.32)

About MYOS Corporation
MYOS is a developmental stage bionutrition and biotherapeutics company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™ (also known as MYO-T12®), the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.

The Company's first commercial product MYO-X™, powered by MYO-T12®, is distributed by Maximum Human Performance (MHP) and is currently available on popular retailer websites including www.mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that MYO-X, as well as future products it envisions, will redefine existing standards for muscle health.

Forward-Looking Statements
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of MYO-T12® and its effects on myostatin inhibition, including our research and development activities including the clinical studies described herein, product and customer demand, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, the continued growth in market expansion and revenue including the expansion into the age management market, the successful entry into new markets including the age management market, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin™ and MYO-X™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the continued growth and expansion of MYO-X in GNC, Vitamin Shoppe and other specialty retail stores, the ability to strengthen our manufacturing relationships and reduce the costs of our products, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Investor and Media Contact:
Jenene Thomas
Investor Relations and Corporate Communications
(973) 509-0444
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
"We are a modern development application platform and we have a suite of products that allow you to application release automation, we do version control, and we do application life cycle management," explained Flint Brenton, CEO of CollabNet, in this SYS-CON.tv interview at DevOps at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
An IoT product’s log files speak volumes about what’s happening with your products in the field, pinpointing current and potential issues, and enabling you to predict failures and save millions of dollars in inventory. But until recently, no one knew how to listen. In his session at @ThingsExpo, Dan Gettens, Chief Research Officer at OnProcess, discussed recent research by Massachusetts Institute of Technology and OnProcess Technology, where MIT created a new, breakthrough analytics model for ...
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Unsecured IoT devices were used to launch crippling DDOS attacks in October 2016, targeting services such as Twitter, Spotify, and GitHub. Subsequent testimony to Congress about potential attacks on office buildings, schools, and hospitals raised the possibility for the IoT to harm and even kill people. What should be done? Does the government need to intervene? This panel at @ThingExpo New York brings together leading IoT and security experts to discuss this very serious topic.
Internet of @ThingsExpo has announced today that Chris Matthieu has been named tech chair of Internet of @ThingsExpo 2017 New York The 7th Internet of @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, New York. Chris Matthieu is the co-founder and CTO of Octoblu, a revolutionary real-time IoT platform recently acquired by Citrix. Octoblu connects things, systems, people and clouds to a global mesh network allowing users to automate and control design flo...
"We analyze the video streaming experience. We are gathering the user behavior in real time from the user devices and we analyze how users experience the video streaming," explained Eric Kim, Founder and CEO at Streamlyzer, in this SYS-CON.tv interview at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
SYS-CON Events has announced today that Roger Strukhoff has been named conference chair of Cloud Expo and @ThingsExpo 2017 New York. The 20th Cloud Expo and 7th @ThingsExpo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "The Internet of Things brings trillions of dollars of opportunity to developers and enterprise IT, no matter how you measure it," stated Roger Strukhoff. "More importantly, it leverages the power of devices and the Internet to enable us all to im...
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, discussed why and how ReadyTalk diverted from healthy revenue and mor...
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Cloud Expo, Inc. has announced today that Andi Mann returns to 'DevOps at Cloud Expo 2017' as Conference Chair The @DevOpsSummit at Cloud Expo will take place on June 6-8, 2017, at the Javits Center in New York City, NY. "DevOps is set to be one of the most profound disruptions to hit IT in decades," said Andi Mann. "It is a natural extension of cloud computing, and I have seen both firsthand and in independent research the fantastic results DevOps delivers. So I am excited to help the great t...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...